

How Guidelines and
Recent Clinical Trial Data Inform
the Modern-Day Treatment of
Advanced **PROSTATE CANCER**

IN-PERSON + VIRTUAL SATELLITE SYMPOSIUM

SATURDAY, JUNE 4, 2022

7:00 PM - 9:00 PM CDT

PROGRAM CHAIR

Robert Dreicer, MD, MS, MACP, FASCO

For more information, visit us at...

gotoper.com



STAY CONNECTED! Follow us @GoToPER and share your thoughts by using #gotoper.

Dear Colleague,

On behalf of Physicians' Education Resource®, LLC (PER®), we would like to welcome you and thank you for choosing to attend **How Guidelines and Recent Clinical Trial Data Inform the Modern-Day Treatment of Advanced Prostate Cancer**.

The past decade has witnessed significant advances in the treatment of advanced/metastatic prostate cancer, particularly for patients with castration-resistant prostate cancer (CRPC), mainly due to a growing insight into the biology of the disease. New treatments allow physicians to target previously unattainable therapeutic goals and treat patients who would have received suboptimal therapy because of a lack of better treatment strategies. In this hybrid satellite program, expert faculty will review the selection and sequencing of drugs to match a patient's clinical profile. They will also discuss and debate optimal treatment sequencing for individual patients using case scenarios. Data on the efficacy and safety of emerging agents, including PARP inhibitors, for metastatic CRPC will be analyzed, and specific information presented at the 2022 Annual Meeting of the American Society of Clinical Oncology that is relevant to the management of CRPC will be outlined.

In working together with PER®, we strive to make this activity, along with all of PER®'s accredited continuing education (CE) activities, both useful and impactful for health care professionals like you who are involved with the care of patients with advanced prostate cancer.

If there is anything additional that you need, if you experience an issue, or if you have an idea for a future activity that would help you in the care of your patients, please let us know.

We could not have our accredited CE activities without you, and we appreciate your commitment to learning about the latest advancements in the treatment of cancer. Let's work together to make this an educational experience that will make a positive difference for our patients!

We hope you enjoy your experience at this first-class PER® symposium and that you can attend another PER® accredited CE activity soon.

Regards,

Robert Dreicer, MD, MS, MACP, FASCO

Professor of Medicine and Urology
University of Virginia School of Medicine
Section Head, Medical Oncology
Associate Director for Clinical Research
Deputy Director, University of Virginia Cancer Center
Co-Director, Paul Mellon Urologic Cancer Institute
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville, VA

Phil Talamo, CHCP

President
Physicians' Education Resource®, LLC
Cranbury, NJ
ptalamo@gotoper.com

AGENDA

7:00 PM	Welcome, Pre-session Survey, Program Overview, Pre-Assessment Questions, and Background on Testing in Prostate Cancer	Robert Dreicer, MD, MS
7:20 PM	Module 1: Practice-Changing Evidence for Non-Metastatic (NM) CRPC	Tomasz M. Beer, MD
7:40 PM	Module 2: Sequencing Therapies in Metastatic (m)CRPC	Robert Dreicer, MD, MS
8:00 PM	Module 3: Evolving Role of PARP Inhibition in Metastatic CRPC	Tanya B. Dorff, MD
8:25 PM	Module 4: Emerging Treatment Landscape in mCRPC	Scott T. Tagawa, MD, MS
8:45 PM	ASCO Annual Meeting Preview	Robert Dreicer, MD, MS
8:50 PM	Program Summary, Post-Assessment Questions	
9:00 PM	Adjourn	

Upcoming PER® Conferences			2022
●	6th Annual International Congress on Oncology & Pathology™: Towards Harmonization of Pathology and Oncology Standards		June 25
●	21st Annual International Congress on the Future of Breast Cancer® East	New York City, NY	July 15-16
●	6th Annual Live Medical Crossfire®: Hematologic Malignancies	New York City, NY	July 16
●	23rd Annual International Lung Cancer Congress®	Huntington Beach, CA	July 28-30
●	21st Annual International Congress on the Future of Breast Cancer® West	San Diego, CA	July 29-30
●	6th Annual School of Nursing Oncology	San Diego, CA	July 29-30
●	20th Annual School of Breast Oncology®	Atlanta, GA	November 3-5
●	40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®	New York City, NY	November 9-11
●	17th Annual New York Lung Cancers Symposium	New York City, NY	November 12
●	7th Annual International Congress on Immunotherapies in Cancer™	New York City, NY	December 10
●	Virtual Conference		
●	In-Person + Virtual Conference		

Target Audience

This educational activity is directed toward oncologists, urologists, nurses, physician assistants, and other health care professionals involved in the treatment of prostate cancer.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

- Explain clinical trial data and evidence-based recommendations for the management of nonmetastatic and metastatic forms of CRPC
- Determine strategies to optimize sequencing of current therapies in the care of patients with CRPC
- Assess recent trial evidence from studies that evaluated novel approaches for CRPC in the context of their impact on evolving paradigms in the field
- Apply proactive strategies to monitor for and manage treatment-associated toxicities in CRPC care settings

Slides/e-Syllabus

Final slides will be uploaded to the e-syllabus on the PER® website by 12 PM EDT Monday, June 6, 2022. To access these materials, please visit <https://www.gotoper.com/prostate0622iss-esyl>.

How to Request Credit

To complete the online evaluation and receive a certificate of credit or participation, please visit <https://www.gotoper.com/prostate0622iss-eval>.

The online evaluation and request for credit will be available immediately following the program and will remain available until September 4, 2022.

Accreditation/Designation of Credit

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 2.0 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Exelixis, Inc.; Lantheus Medical Imaging, Inc.; and Sanofi Genzyme.

Thank you for attending **How Guidelines and Recent Clinical Trial Data Inform the Modern-Day Treatment of Advanced Prostate Cancer!**

To register for upcoming accredited CE live activities
or to view our online accredited CE activities, please visit www.gotoper.com.

We appreciate your attendance and look forward to seeing you at future
PER® accredited CE activities.

Faculty, Staff, and Planners' Disclosures

The following individuals have no relevant financial relationships with ineligible companies to disclose: the staff of Physicians' Education Resource®, LLC.

The following individuals have relevant financial relationships with ineligible companies to disclose*:

Faculty	Grant/Research Support	Consultant	Shareholder
Tomasz M. Beer, MD, FACP	Funding paid to institution: Alliance Foundation Trials, Astellas Pharma, Bayer, Boehringer Ingelheim, Corcept Therapeutics, Endocyte Inc, Exact Sciences Corp, Freenome, Grail Inc, Harpoon Therapeutics, Janssen Research & Development, Medivation Inc, Merck, SOTIO, Theraclone Sciences/ OncoResponse, Zenith Epigenetics	AbbVie, Amgen, Arvinas, Astellas Pharma, AstraZeneca, Bayer, Bristol-Myers Squibb, Constellation, Dantari Pharmaceuticals, GlaxoSmithKline, Grail Inc, Janssen, Myovant Sciences, Pfizer, Sanofi, Sapience Therapeutics	Arvinas Inc, Salarius Pharmaceuticals
Tanya Dorff, MD		SeaGen, Exelixis, AstraZeneca, Pfizer, Astellas, Janssen	
Robert Dreicer, MD, MS, MACP, FASCO		Astellas, Astra Zeneca, Aveo, Bayer, Bristol Myers Squibb, Exelixis, EMD Serono, Gilead, Hengrui, Hinova, Janssen, Merck, Myovant, Pfizer, Propella, Sanofi Genzyme, Seattle Genetics, Tavant	
Scott T. Tagawa, MD, MS, FACP	Sanofi, Medivation, Astellas, Janssen, Amgen, Progenics, Dendreon, Lilly, Genentech, NewLink, Bristol Myers Squibb, Inovio, AstraZeneca, Immunomedics, Aveo, Rexahn, Atlab, Boehringer Ingelheim, Millennium, Bayer, Merck, AbbVie, Karyopharm, Endocyte, Clovis, Seattle Genetics, Novartis, Gilead, POINT Biopharma	Sanofi, Medivation/Astellas, Dendreon, Janssen, Genentech, Bayer, Endocyte, Eisai, Immunomedics, Karyopharm, AbbVie, Tolmar, Seattle Genetics, Amgen,	Alkido

**Information accurate at time of posting*

PER® has identified and mitigated all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This accredited CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing medical and/or nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to the diagnostic, treatment, and management options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any of the companies that provided commercial support for this activity.

Physician Payments Sunshine Act

PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.

Program Chair



Robert Dreicer, MD, MS, MACP, FASCO

Professor of Medicine and Urology
 University of Virginia School of Medicine
 Section Head, Medical Oncology
 Associate Director for Clinical Research
 Deputy Director, University of Virginia Cancer Center
 Co-Director, Paul Mellon Urologic Cancer Institute
 Professor of Medicine and Urology
 University of Virginia School of Medicine
 Charlottesville, VA

Robert Dreicer, MD, MS, MACP, FASCO, is the associate director for clinical research and the deputy director of the University of Virginia Cancer Center. He serves as section head of medical oncology and co-director of the Paul Mellon Urologic Institute and is a professor of medicine and urology at the University of Virginia School of Medicine. He previously served as chair of the Department of Solid Tumor Oncology at the Cleveland Clinic and deputy associate director for clinical research for the Case Comprehensive Cancer Center.

Dr Dreicer's areas of specialization are the management of genitourinary malignancies and the design and conduct of clinical trials in urologic oncology. He received his medical degree from the University of Texas Medical School at Houston. He completed an internal medicine residency at Indiana University in Indianapolis, followed by a medical oncology fellowship at the University of Wisconsin Clinical Cancer Center in Madison. Dr Dreicer has published widely in genitourinary oncology and has served as principal investigator of a large number of studies in genitourinary neoplasms.

Faculty



Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical Oncology
 Grover C. Bagby Chair of Prostate Cancer Research
 Deputy Director
 Chief Medical Officer, Center for Early Detection Advanced Research
 Oregon Health & Science University Knight Cancer Institute
 Oregon Health & Science University School of Medicine
 Portland, OR

Tomasz (Tom) Beer, MD, FACP, is a professor of Medicine and Grover C. Bagby Endowed Chair of Prostate Cancer Research in the division of hematology/medical oncology, where he leads the prostate cancer research program, which encompasses basic research, translational research, clinical trials of novel therapeutic strategies in prostate cancer, and studies aimed at enhancing cancer survivorship. He has authored or co-authored more than 250 peer reviewed articles on prostate cancer. Dr Beer is particularly known for investigations of targeted therapies and immunotherapies in prostate cancer, including the calcitriol receptor, the androgen receptor, CTLA-4 and PD-1 inhibitors, PSMA, and others. He led the global randomized trial of enzalutamide vs placebo, which demonstrated substantial improvements in overall and progression-free survival and quality of life and served as the basis for a global change in the standard of care for advanced prostate cancer. Dr Beer serves as deputy director of the Oregon Health & Science University (OHSU) Knight Cancer Institute and as chief medical officer for the Center for Early Detection Advanced Research (CEDAR) within Knight. At CEDAR, Dr. Beer fosters collaborations to advance discoveries in the early detection of cancer and leads clinical trials of multiomic blood-based tests for the early detection of cancer. Dr Beer cares for men with prostate cancer at OHSU and at the Portland VA Medical Center.


Tanya Dorff, MD

Section Chief, Genitourinary Disease Program
Associate Professor, Department of Medical Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center
Duarte, CA

Tanya Barauskas Dorff, MD, is an associate professor in the Department of Medical Oncology and Therapeutics Research and serves as section chief of the genitourinary disease program at the City of Hope Comprehensive Cancer Center. She is an internationally recognized leader in prostate cancer and is renowned for her work in other genitourinary tumor types.

Dr Dorff attended the University of California, Los Angeles, School of Medicine. She completed her internal medicine residency at Mount Sinai Hospital in New York and subspecialty training in hematology/oncology at the Los Angeles University of Southern California (USC) Medical Center.

Dr Dorff was on the faculty at USC for nearly 10 years, and she amassed over 75 publications. She is heavily involved in trials of immunotherapy and treatment combinations. She has also worked on trials examining lifestyle and treatment adverse effects. Recently, she was awarded a Prostate Cancer Foundation/Pfizer grant to study talazoparib specifically in an ethnically diverse population. She leads City of Hope's joint effort with the Prostate Cancer Foundation to develop chimeric antigen receptor T cells to target prostate cancer tissue. She is also involved in investigations of circulating tumor DNA as a biomarker and the role of the microbiome in earlier stage disease.


Scott T. Tagawa, MD, MS, FACP

Professor of Medicine and Urology
Medical Director, Genitourinary Oncology Research Program
Associate Director of Clinical Research, Division of Hematology and Medical Oncology
Medical Director, Cancer Clinical Trials Office of the Meyer Cancer Center
Chair, Feasibility Committee for Cancer Clinical Research
Weill Cornell Medicine
New York, NY

Scott T. Tagawa, MD, MS, FACP, is a professor of Medicine and Urology; medical director of the genitourinary oncology research program; associate director of clinical research in the division of hematology and medical oncology; medical director of the cancer clinical trials office of the Meyer Cancer Center; and chair of the Feasibility Committee for Cancer Clinical Research at Weill Cornell Medicine.

Dr Tagawa received his medical degree at the University of Southern California School of Medicine. After completing his internship and residency training there, he received fellowship training in hematology and medical oncology. His research involves clinical and translational investigations of genitourinary tumors and thrombosis in malignancy. As the medical director of the genitourinary oncology research program, Dr Tagawa leads clinical trials in prostate, bladder, and kidney cancer and the prevention and treatment of thrombosis associated with cancer. He specializes in drug development in genitourinary malignancies with a particular interest cell-surface targeting, including prostate-specific membrane antigen theranostics.

ASCO Direct™

HIGHLIGHTS

2022 Official Annual Meeting Review

Learn from leading experts about important, potentially practice-changing data in oncology and hematology.

Dallas, TX
June 18

Charlotte, NC
July 9

Nashville, TN
July 9

New York, NY
July 23

VIRTUAL
OPTIONS
AVAILABLE

40% off registration! Use code **ADH22**



Scan with smartphone
to explore the series

PER®
Physicians'
Education
Resource, LLC
gotoper.com

**CELEBRATE THE 40TH ANNIVERSARY
OF CFS® LIVE IN NYC**

**40th Annual
CFS**®

Chemotherapy Foundation
SYMPOSIUM

Innovative Cancer Therapy for Tomorrow®

SAVE
THE
DATE!

NOVEMBER 9 – 11, 2022
New York Marriott Marquis • New York, NY
In-person + Virtual Conference

This activity
is approved
for AMA PRA
Category 1
Credit™.



100 EXPERT
FACULTY
MEMBERS



25 TUMOR
TYPES



3 DAYS



1 MEETING

35% off registration! Use code **CFS22BF**



Scan with smartphone or visit the link below
gotoper.com/cfs22

PER®
Physicians'
Education
Resource, LLC
gotoper.com